This week’s announcement from Boehringer Ingelheim that it is acquiring, after entry into clinical trials, the key asset of FX125L from Funxional Therapeutics, may perhaps change the language of pharmaceutical discovery.
This week’s announcement from Boehringer Ingelheim that it is acquiring, after entry into clinical trials, the key asset of FX125L from Funxional Therapeutics, may perhaps change the language of pharmaceutical discovery.